Mariotto, A. B., Enewold, L., Zhao, J., Zeruto, C. A. & Yabroff, K. R. Medical care costs associated with cancer survivorship in the United States. Cancer Epidemiol. Biomark. Prev. 29, 1304–1312 (2020).
Google Scholar
Plotkin, S. A. & Plotkin, S. L. The development of vaccines: how the past led to the future. Nat. Rev. Microbiol. 9, 889–893 (2011).
Google Scholar
Shahzamani, K. et al. Vaccine design and delivery approaches for COVID-19. Int. Immunopharmacol. 100, 108086 (2021).
Google Scholar
Laureano, R. S. et al. Trial watch: dendritic cell (DC)-based immunotherapy for cancer. Oncoimmunology 11, 2096363 (2022).
Google Scholar
Schiller, J. T. et al. Cancer vaccines. Cancer Cell 40, 559–564 (2022). This review provides an overview of recent advancements in cancer vaccines.
Google Scholar
Singer, D. S. A new phase of the Cancer Moonshot to end cancer as we know it. Nat. Med. 28, 1345–1347 (2022). This article underscores the pivotal role of the Cancer Moonshot initiative in focusing on prevention approaches.
Google Scholar
Fact sheet: President Biden reignites cancer moonshot to end cancer as we know it. The White House. (2022).
Schreiber, R. D., Old, L. J. & Smyth, M. J. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 331, 1565–1570 (2011). This article establishes the concept of cancer immunoediting, which highlights the dual role of the immune system in both suppressing tumour formation and promoting cancer development.
Google Scholar
Waldman, A. D., Fritz, J. M. & Lenardo, M. J. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat. Rev. Immunol. 20, 651–668 (2020).
Google Scholar
Beatty, G. L. & Gladney, W. L. Immune escape mechanisms as a guide for cancer immunotherapy. Clin. Cancer Res. 21, 687–692 (2015).
Google Scholar
Bol, K. F., Schreibelt, G., Gerritsen, W. R., de Vries, I. J. & Figdor, C. G. Dendritic cell-based immunotherapy: state of the art and beyond. Clin. Cancer Res. 22, 1897–1906 (2016).
Google Scholar
Hiraoka, N., Onozato, K., Kosuge, T. & Hirohashi, S. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin. Cancer Res. 12, 5423–5434 (2006).
Google Scholar
Beatty, P. L. et al. Immunobiology and immunosurveillance in patients with intraductal papillary mucinous neoplasms (IPMNs), premalignant precursors of pancreatic adenocarcinomas. Cancer Immunol. Immunother. 65, 771–778 (2016).
Google Scholar
Gil Del Alcazar, C. R. et al. Immune escape in breast cancer during in situ to invasive carcinoma transition. Cancer Discov. 7, 1098–1115 (2017).
Google Scholar
Mascaux, C. et al. Immune evasion before tumour invasion in early lung squamous carcinogenesis. Nature 571, 570–575 (2019).
Google Scholar
Chang, M. H. et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N. Engl. J. Med. 336, 1855–1859 (1997).
Google Scholar
Chang, M. H. et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J. Natl Cancer Inst. 101, 1348–1355 (2009).
Google Scholar
Cheng, L., Wang, Y. & Du, J. Human papillomavirus vaccines: an updated review. Vaccines 8, 391 (2020).
Google Scholar
de Sanjose, S., Brotons, M. & Pavon, M. A. The natural history of human papillomavirus infection. Best Pract. Res. Clin. Obstet. Gynaecol. 47, 2–13 (2018).
Google Scholar
Ventura, C. et al. The effectiveness of therapeutic vaccines for the treatment of cervical intraepithelial neoplasia 3: a systematic review and meta-analysis. Vaccines 10, 1560 (2022).
Google Scholar
Page, K. et al. Randomized trial of a vaccine regimen to prevent chronic HCV infection. N. Engl. J. Med. 384, 541–549 (2021).
Google Scholar
Sokal, E. M. et al. Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J. Infect. Dis. 196, 1749–1753 (2007).
Google Scholar
Escalante, G. M., Mutsvunguma, L. Z., Muniraju, M., Rodriguez, E. & Ogembo, J. G. Four decades of prophylactic EBV vaccine research: a systematic review and historical perspective. Front. Immunol. 13, 867918 (2022).
Google Scholar
Xu, D. et al. Development of a therapeutic vaccine targeting Merkel cell polyomavirus capsid protein VP1 against Merkel cell carcinoma. NPJ Vaccines 6, 119 (2021).
Google Scholar
Janz, A. et al. Infectious Epstein-Barr virus lacking major glycoprotein BLLF1 (gp350/220) demonstrates the existence of additional viral ligands. J. Virol. 74, 10142–10152 (2000).
Google Scholar
The Lancet Gastroenterology Hepatology. The hunt for a vaccine for hepatitis C virus continues. Lancet Gastroenterol. Hepatol. 6, 253 (2021).
Google Scholar
Dieye, Y., Nguer, C. M., Thiam, F., Diouara, A. A. M. & Fall, C. Recombinant helicobacter pylori vaccine delivery vehicle: a promising tool to treat infections and combat antimicrobial resistance. Antibiotics 11, 1701 (2022).
Google Scholar
Goh, K. L., Chan, W. K., Shiota, S. & Yamaoka, Y. Epidemiology of Helicobacter pylori infection and public health implications. Helicobacter 16, 1–9 (2011).
Google Scholar
Hu, Y., Zhu, Y. & Lu, N. H. The management of Helicobacter pylori infection and prevention and control of gastric cancer in China. Front. Cell Infect. Microbiol. 12, 1049279 (2022).
Google Scholar
Stone, J. et al. The potential impact of a hepatitis C vaccine for people who inject drugs: is a vaccine needed in the age of direct-acting antivirals? PLoS One 11, e0156213 (2016).
Google Scholar
Toor, J. et al. Lives saved with vaccination for 10 pathogens across 112 countries in a pre-COVID-19 world. eLife 10, e67635 (2021).
Google Scholar
Scott, N. et al. The case for a universal hepatitis C vaccine to achieve hepatitis C elimination. BMC Med. 17, 175 (2019).
Google Scholar
Lang, F., Schrörs, B., Löwer, M., Türeci, Ö. & Sahin, U. Identification of neoantigens for individualized therapeutic cancer vaccines. Nat. Rev. Drug Discov. 21, 261–282 (2022).
Google Scholar
Vonka, V. & Hirsch, I. Prophylactic vaccines against cancers of non-infectious origin: a dream or a real possibility? Cent. Eur. J. Public Health 29, 247–258 (2021).
Google Scholar
Chial, H. Proto-oncogenes to oncogenes to cancer. Nat. Educ. 1, 33 (2008).
Naderi-Azad, S. & Sullivan, R. The potential of BRAF-targeted therapy combined with immunotherapy in melanoma. Expert Rev. Anticancer Ther. 20, 131–136 (2020).
Google Scholar
Gjertsen, M. K. et al. Ex vivo ras peptide vaccination in patients with advanced pancreatic cancer: results of a phase I/II study. Int. J. Cancer 65, 450–453 (1996).
Google Scholar
Toubaji, A. et al. Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers. Cancer Immunol. Immunother. 57, 1413–1420 (2008).
Google Scholar
Pan, J. et al. Immunoprevention of KRAS-driven lung adenocarcinoma by a multipeptide vaccine. Oncotarget 8, 82689–82699 (2017).
Google Scholar
Pan, J. et al. Potentiation of Kras peptide cancer vaccine by avasimibe, a cholesterol modulator. EBioMedicine 49, 72–81 (2019).
Google Scholar
Saeterdal, I. et al. Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. Proc. Natl Acad. Sci. USA 98, 13255–13260 (2001). This article describes the identification of frameshift mutation-derived peptides as tumour-specific antigens in both inherited and spontaneous CRC, providing a foundation for the development of targeted immunotherapies.
Google Scholar
Gebert, J. et al. Recurrent frameshift neoantigen vaccine elicits protective immunity with reduced tumor burden and improved overall survival in a Lynch syndrome mouse model. Gastroenterology 161, 1288–1302.e13 (2021).
Google Scholar
Zhang, J., Shen, L. & Johnston, S. A. Using frameshift peptide arrays for cancer neo-antigens screening. Sci. Rep. 8, 17366 (2018).
Google Scholar
Katsnelson, A. Preventive cancer vaccine based on neoantigens gets put to the test. ACS Cent. Sci. 7, 1288–1291 (2021).
Google Scholar
Appin, C. L. et al. Whole tumor analysis reveals early origin of the TERT promoter mutation and intercellular heterogeneity in TERT expression. Neuro-Oncology 26, 640–652 (2024).
Google Scholar
Stevers, N. O. & Costello, J. F. Telomeres in glioma: maintenance mechanisms to therapeutic potential. Neuro-Oncology 26, 1025–1026 (2024).
Google Scholar
Kuchenbaecker, K. B. et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317, 2402–2416 (2017). This article provides an important analysis of the risks of breast, ovarian and contralateral breast cancer in BRCA1 and BRCA2 mutation carriers, providing valuable data for risk assessment and personalized management strategies for individuals with these mutations.
Google Scholar
Skolnik, J. P858 An open-label, multi-center trial of INO-5401 and INO-9012 delivered by electroporation (EP) in combination with cemiplimab in subjects with newly-diagnosed glioblastoma (GBM). J. Immunother. Cancer 8, (2020).
Tuohy, V. K., Johnson, J. M. & Mazumder, S. Primary immunoprevention of adult onset cancers by vaccinating against retired tissue-specific self-proteins. Semin. Immunol. 47, 101392 (2020).
Google Scholar
Tuohy, V. K. et al. Targeted vaccination against human alpha-lactalbumin for immunotherapy and primary immunoprevention of triple negative breast cancer. Cancers 8, 56 (2016).
Google Scholar
Jaini, R. et al. An autoimmune-mediated strategy for prophylactic breast cancer vaccination. Nat. Med. 16, 799–803 (2010).
Google Scholar
Serrano, D., Lazzeroni, M. & Bonanni, B. Cancer chemoprevention: much has been done, but there is still much to do. State of the art and possible new approaches. Mol. Oncol. 9, 1008–1017 (2015).
Google Scholar
Vlad, A. M., Kettel, J. C., Alajez, N. M., Carlos, C. A. & Finn, O. J. MUC1 immunobiology: from discovery to clinical applications. Adv. Immunol. 82, 249–293 (2004).
Google Scholar
Ho, S. B., Ewing, S. L., Montgomery, C. K. & Kim, Y. S. Altered mucin core peptide immunoreactivity in the colon polyp-carcinoma sequence. Oncol. Res. 8, 53–61 (1996).
Google Scholar
Kimura, T. et al. MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study. Cancer Prev. Res. 6, 18–26 (2013).
Google Scholar
Lohmueller, J. J. et al. Antibodies elicited by the first non-viral prophylactic cancer vaccine show tumor-specificity and immunotherapeutic potential. Sci. Rep. 6, 31740 (2016).
Google Scholar
Schoen, R. E. et al. Randomized, double-blind, placebo-controlled trial of MUC1 peptide vaccine for prevention of recurrent colorectal adenoma. Clin. Cancer Res. 29, 1678–1688 (2023).
Google Scholar
Ramanathan, R. K. et al. Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunol. Immunother. 54, 254–264 (2005).
Google Scholar
Goydos, J. S., Elder, E., Whiteside, T. L., Finn, O. J. & Lotze, M. T. A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J. Surg. Res. 63, 298–304 (1996).
Google Scholar
Gao, T., Cen, Q. & Lei, H. A review on development of MUC1-based cancer vaccine. Biomed. Pharmacother. 132, 110888 (2020).
Google Scholar
Cheever, M. A. et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin. Cancer Res. 15, 5323–5337 (2009).
Google Scholar
Tovey, S. M. et al. Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours. Br. J. Cancer 100, 680–683 (2009).
Google Scholar
Godoy-Ortiz, A. et al. Deciphering HER2 breast cancer disease: biological and clinical implications. Front. Oncol. 9, 1124 (2019).
Google Scholar
Harada, S. et al. The significance of HER-2/neu receptor positivity and immunophenotype in ductal carcinoma in situ with early invasive disease. J. Surg. Oncol. 104, 458–465 (2011).
Google Scholar
Lowenfeld, L. et al. Dendritic cell vaccination enhances immune responses and induces regression of HER2(pos) DCIS independent of route: results of randomized selection design trial. Clin. Cancer Res. 23, 2961–2971 (2017).
Google Scholar
Gallus, M., Kwok, D., Lakshmanachetty, S., Yamamichi, A. & Okada, H. Immunotherapy approaches in isocitrate-dehydrogenase-mutant low-grade glioma. Cancers 15, 3726 (2023).
Google Scholar
Okada, H. et al. Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC. Clin. Cancer Res. 21, 286–294 (2015).
Google Scholar
Ogino, H. et al. Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas. J. Clin. Invest. 132, e151239 (2022).
Google Scholar
Dutoit, V. et al. Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy. Brain 135, 1042–1054 (2012).
Google Scholar
Dutoit, V. et al. Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma. Oncoimmunology 7, e1391972 (2018).
Google Scholar
Saijo, A. et al. A combinatory vaccine with IMA950 plus varlilumab promotes effector memory T-cell differentiation in the peripheral blood of patients with low-grade gliomas. Neuro-Oncology 26, 335–347 (2024).
Google Scholar
Lonial, S., Rajkumar, S. V. & Mateos, M. V. Risk stratified management approaches for smouldering multiple myeloma: clinical research becomes clinical practice. Lancet Haematol. 9, E162–E165 (2022).
Google Scholar
Lonial, S. et al. Randomized trial of lenalidomide versus observation in smoldering multiple myeloma. J. Clin. Oncol. 38, 1126–1137 (2020).
Google Scholar
Mateos, M. V. et al. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. Lancet Oncol. 17, 1127–1136 (2016).
Google Scholar
Mateos, M. V. et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N. Engl. J. Med. 369, 438–447 (2013).
Google Scholar
Cherry, B. M. et al. Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study. Leuk. Lymphoma 54, 2215–2218 (2013).
Google Scholar
Vaxman, I. & Gertz, M. A. How I approach smoldering multiple myeloma. Blood 140, 828–838 (2022).
Google Scholar
Buonaguro, L. & Tagliamonte, M. Peptide-based vaccine for cancer therapies. Front. Immunol. 14, 1210044 (2023).
Google Scholar
Rojas, L. A. et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 618, 144–150 (2023). This article demonstrated the potential of personalized vaccines for targeting tumours in this difficult-to-treat cancer type.
Google Scholar
Wang, C. & Yuan, F. A comprehensive comparison of DNA and RNA vaccines. Adv. Drug Deliv. Rev. 210, 115340 (2024).
Google Scholar
Sayour, E. J., Boczkowski, D., Mitchell, D. A. & Nair, S. K. Cancer mRNA vaccines: clinical advances and future opportunities. Nat. Rev. Clin. Oncol. 21, 489–500 (2024).
Google Scholar
Duan, Z. et al. Advances, opportunities and challenges in developing therapeutic cancer vaccines. Crit. Rev. Oncol. Hematol. 193, 104198 (2023).
Google Scholar
Liu, D. Q., Che, X. Y., Wang, X. X., Ma, C. Y. & Wu, G. Z. Tumor vaccines: unleashing the power of the immune system to fight cancer. Pharmaceuticals 16, 1384 (2023).
Google Scholar
De Keersmaecker, B. et al. TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma. J. Immunother. Cancer 8, (2020).
Jansen, Y. et al. A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases. Cancer Immunol. Immunother. 69, 2589–2598 (2020).
Google Scholar
Butterfield, L. H. et al. Multiple antigen-engineered DC vaccines with or without IFNalpha to promote antitumor immunity in melanoma. J. Immunother. Cancer 7, 113 (2019).
Google Scholar
Nagai, K. et al. Dendritic cell-based immunotherapy pulsed with Wilms tumor 1 peptide and mucin 1 as an adjuvant therapy for pancreatic ductal adenocarcinoma after curative resection: a phase I/IIa clinical trial. Anticancer. Res. 40, 5765–5776 (2020).
Google Scholar
Tanyi, J. L. et al. Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. Sci. Transl. Med 10, eaao5931 (2018).
Google Scholar
Yu, Y. J. et al. Preliminary clinical study of personalized neoantigen vaccine therapy for microsatellite stability (MSS)-advanced colorectal cancer. Cancer Immunol. Immunother. 72, 2045–2056 (2023).
Google Scholar
Awad, M. M. et al. Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer. Cancer Cell 40, 1010–1026.e11 (2022).
Google Scholar
Kantoff, P. W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411–422 (2010).
Google Scholar
Bezu, L. et al. Trial watch: peptide-based vaccines in anticancer therapy. Oncoimmunology 7, e1511506 (2018).
Google Scholar
Lin, M. J. et al. Cancer vaccines: the next immunotherapy frontier. Nat. Cancer 3, 911–926 (2022).
Google Scholar
Sellars, M. C., Wu, C. J. & Fritsch, E. F. Cancer vaccines: building a bridge over troubled waters. Cell 185, 2770–2788 (2022).
Google Scholar
Harari, A., Graciotti, M., Bassani-Sternberg, M. & Kandalaft, L. E. Antitumour dendritic cell vaccination in a priming and boosting approach. Nat. Rev. Drug Discov. 19, 635–652 (2020). This review highlights the effectiveness of using vaccination in a prime-and-boost approach integrating it in the standard of care.
Google Scholar
Nava, S., Lisini, D., Frigerio, S. & Bersano, A. Dendritic cells and cancer immunotherapy: the adjuvant effect. Int. J. Mol. Sci. 22, 12339 (2021).
Google Scholar
Bai, R. et al. Mechanisms of cancer resistance to immunotherapy. Front. Oncol. 10, 1290 (2020).
Google Scholar
Figlin, R. A. et al. Results of the ADAPT phase 3 study of rocapuldencel-t in combination with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma. Clin. Cancer Res. 26, 2327–2336 (2020).
Google Scholar
Vogelzang, N. J. et al. Efficacy and safety of autologous dendritic cell-based immunotherapy, docetaxel, and prednisone vs placebo in patients with metastatic castration-resistant prostate cancer: the VIABLE phase 3 randomized clinical trial. JAMA Oncol. 8, 546–552 (2022).
Google Scholar
Terasaki, M. et al. Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen-A24 with recurrent or progressive glioblastoma multiforme. J. Clin. Oncol. 29, 337–344 (2011).
Google Scholar
Reardon, D. A. et al. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the checkmate 143 phase 3 randomized clinical trial. JAMA Oncol. 6, 1003–1010 (2020).
Google Scholar
Lim, M. et al. Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter. Neuro-Oncology 24, 1935–1949 (2022).
Google Scholar
Bausart, M., Préat, V. & Malfanti, A. Immunotherapy for glioblastoma: the promise of combination strategies. J. Exp. Clin. Cancer Res. 41, (2022).
Weber, J. S. et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet 403, 632–644 (2024).
Google Scholar
Nanni, P. et al. Antimetastatic activity of a preventive cancer vaccine. Cancer Res. 67, 11037–11044 (2007).
Google Scholar
Czerniecki, B. J. et al. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res. 67, 1842–1852 (2007).
Google Scholar
Koski, G. K. et al. A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer. J. Immunother. 35, 54–65 (2012).
Google Scholar
Sharma, A. et al. HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ. Cancer 118, 4354–4362 (2012).
Google Scholar
Fracol, M. et al. Response to HER-2 pulsed DC1 vaccines is predicted by both HER-2 and estrogen receptor expression in DCIS. Ann. Surg. Oncol. 20, 3233–3239 (2013).
Google Scholar
Nooka, A. K. et al. Assessment of safety and immunogenicity of PVX-410 vaccine with or without lenalidomide in patients with smoldering multiple myeloma: a nonrandomized clinical trial. JAMA Oncol. 4, e183267 (2018).
Google Scholar
Ritvo, P. et al. Vaccines in the public eye. Nat. Med. 11, S20–S24 (2005).
Google Scholar
Maeng, H. M. & Berzofsky, J. A. Strategies for developing and optimizing cancer vaccines. F1000Res 8, (2019).
Stanton, S. E., Castle, P. E., Finn, O. J., Sei, S. & Emens, L. A. Advances and challenges in cancer immunoprevention and immune interception. J. Immunother. Cancer 12, e007815 (2024).
Google Scholar
Chen, B. et al. Differential pre-malignant programs and microenvironment chart distinct paths to malignancy in human colorectal polyps. Cell 184, 6262–6280.e26 (2021).
Google Scholar
Becker, W. R. et al. Single-cell analyses define a continuum of cell state and composition changes in the malignant transformation of polyps to colorectal cancer. Nat. Genet. 54, 985–995 (2022).
Google Scholar
Nirmal, A. J. et al. The spatial landscape of progression and immunoediting in primary melanoma at single-cell resolution. Cancer Discov. 12, 1518–1541 (2022).
Google Scholar
Risom, T. et al. Transition to invasive breast cancer is associated with progressive changes in the structure and composition of tumor stroma. Cell 185, 299–310.e18 (2022).
Google Scholar
Strand, S. H. et al. Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: analysis of TBCRC 038 and RAHBT cohorts. Cancer Cell 40, 1521–1536.e7 (2022).
Google Scholar
Blass, E. & Ott, P. A. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat. Rev. Clin. Oncol. 18, 215–229 (2021).
Google Scholar
Fox, B. A. et al. Cancer’s dark matter: lighting the abyss unveils universe of new therapies. Clin. Cancer Res. 29, 2173–2175 (2023).
Google Scholar
Kwok, D. W. et al. Tumor-wide RNA splicing aberrations generate immunogenic public neoantigens. Preprint at bioRxiv (2023).
Google Scholar
Chong, C. et al. Integrated proteogenomic deep sequencing and analytics accurately identify non-canonical peptides in tumor immunopeptidomes. Nat. Commun. 11, 1293 (2020).
Google Scholar
Lozano-Rabella, M. et al. Exploring the immunogenicity of non-canonical HLA-I tumor ligands identified through proteogenomics. Clin. Cancer Res. 29, 2250–2265 (2023).
Google Scholar
Chiffelle, J. & Harari, A. Personalized cancer T-cell therapy takes the stage, mirroring vaccine success. J. Exp. Med. 221, e20240854 (2024). This article highlights the growing success of personalized T cell therapies in cancer treatment, drawing parallels to the advances made with cancer vaccines and emphasizing the potential for tailored immunotherapies to revolutionize cancer care.
Google Scholar
Petremand, R. et al. Identification of clinically relevant T cell receptors for personalized T cell therapy using combinatorial algorithms. Nat. Biotechnol. (2024).
Google Scholar
Cohly, H. H., Morrison, D. R. & Atassi, M. Z. Antigen presentation by non-immune B-cell hybridoma clones: presentation of synthetic antigenic sites reveals clones that exhibit no specificity and clones that present only one epitope. Immunol. Invest. 18, 987–992 (1989).
Google Scholar
Schirmer, D. et al. Transgenic antigen-specific, HLA-A*02:01-allo-restricted cytotoxic T cells recognize tumor-associated target antigen STEAP1 with high specificity. Oncoimmunology 5, e1175795 (2016).
Google Scholar
Kula, T. et al. T-scan: a genome-wide method for the systematic discovery of T cell epitopes. Cell 178, 1016–1028.e3 (2019).
Google Scholar
Li, G. et al. T cell antigen discovery via trogocytosis. Nat. Methods 16, 183–190 (2019).
Google Scholar
Maruvka, Y. E. et al. Analysis of somatic microsatellite indels identifies driver events in human tumors. Nat. Biotechnol. 35, 951–959 (2017).
Google Scholar
Haasl, R. J. & Payseur, B. A. Remarkable selective constraints on exonic dinucleotide repeats. Evolution 68, 2737–2744 (2014).
Google Scholar
Garbe, Y., Maletzki, C. & Linnebacher, M. An MSI tumor specific frameshift mutation in a coding microsatellite of MSH3 encodes for HLA-A0201-restricted CD8+ cytotoxic T cell epitopes. PLoS One 6, e26517 (2011).
Google Scholar
Roudko, V. et al. Shared immunogenic poly-epitope frameshift mutations in microsatellite unstable tumors. Cell 183, 1634–1649.e17 (2020).
Google Scholar
Saeterdal, I., Gjertsen, M. K., Straten, P., Eriksen, J. A. & Gaudernack, G. A TGF betaRII frameshift-mutation-derived CTL epitope recognised by HLA-A2-restricted CD8+ T cells. Cancer Immunol. Immunother. 50, 469–476 (2001).
Google Scholar
Bonneville, R. et al. Landscape of microsatellite instability across 39 cancer types. JCO Precis. Oncol. 2017, (2017).
Chapman, A. M., Sun, K. Y., Ruestow, P., Cowan, D. M. & Madl, A. K. Lung cancer mutation profile of EGFR, ALK, and KRAS: meta-analysis and comparison of never and ever smokers. Lung Cancer 102, 122–134 (2016).
Google Scholar
Smolle, E. & Pichler, M. Non-smoking-associated lung cancer: a distinct entity in terms of tumor biology, patient characteristics and impact of hereditary cancer predisposition. Cancers 11, 204 (2019).
Google Scholar
Kusnierczyk, P. Genetic differences between smokers and never-smokers with lung cancer. Front. Immunol. 14, 1063716 (2023).
Google Scholar
de Alencar, V. T. L., Figueiredo, A. B., Corassa, M., Gollob, K. J. & Cordeiro de Lima, V. C. Lung cancer in never smokers: tumor immunology and challenges for immunotherapy. Front. Immunol. 13, 984349 (2022).
Google Scholar
Mazieres, J. et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J. Clin. Oncol. 31, 1997–2003 (2013).
Google Scholar
Soda, M. et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448, 561–566 (2007).
Google Scholar
Wong, D. W. et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 115, 1723–1733 (2009).
Google Scholar
Shaw, A. T. et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J. Clin. Oncol. 27, 4247–4253 (2009).
Google Scholar
Fasanelli, F. et al. Hypomethylation of smoking-related genes is associated with future lung cancer in four prospective cohorts. Nat. Commun. 6, 10192 (2015).
Google Scholar
Xie, J. et al. Relationship between HLA genetic variations, COVID-19 vaccine antibody response, and risk of breakthrough outcomes. Nat. Commun. 15, 4031 (2024).
Google Scholar
Tay, G. K. et al. HLA class I associations with the severity of COVID-19 disease in the United Arab Emirates. PLoS One 18, e0285712 (2023).
Google Scholar
Filip, I. et al. Pervasiveness of HLA allele-specific expression loss across tumor types. Genome Med. 15, 8 (2023).
Google Scholar
Crews, D. W., Dombroski, J. A. & King, M. R. Prophylactic cancer vaccines engineered to elicit specific adaptive immune response. Front. Oncol. 11, 626463 (2021).
Google Scholar
Bhardwaj, P., Bhatia, E., Sharma, S., Ahamad, N. & Banerjee, R. Advancements in prophylactic and therapeutic nanovaccines. Acta Biomater. 108, 1–21 (2020).
Google Scholar
Lorentzen, C. L., Haanen, J. B., Met, O. & Svane, I. M. Clinical advances and ongoing trials on mRNA vaccines for cancer treatment. Lancet Oncol. 23, e450–e458 (2022).
Google Scholar
Pulendran, B., P, S. A. & O’Hagan, D. T. Emerging concepts in the science of vaccine adjuvants. Nat. Rev. Drug Discov. 20, 454–475 (2021).
Google Scholar
Lollini, P. L., Cavallo, F., Nanni, P. & Forni, G. Vaccines for tumour prevention. Nat. Rev. Cancer 6, 204–216 (2006).
Google Scholar
Cory, L. et al. Effects of educational interventions on human papillomavirus vaccine acceptability: a randomized controlled trial. Obstet. Gynecol. 134, 376–384 (2019).
Google Scholar
Brewer, N. T. et al. Announcements versus conversations to improve HPV vaccination coverage: a randomized trial. Pediatrics 139, (2017).
Thanasa, E. et al. Awareness regarding human papilloma virus among health professionals and will to accept vaccination: a systematic review. Cureus 14, e30855 (2022).
Google Scholar
Spadaro, M. et al. Cure of mammary carcinomas in Her-2 transgenic mice through sequential stimulation of innate (neoadjuvant interleukin-12) and adaptive (DNA vaccine electroporation) immunity. Clin. Cancer Res. 11, 1941–1952 (2005).
Google Scholar
Ye, X., McCarrick, J., Jewett, L. & Knowles, B. B. Timely immunization subverts the development of peripheral nonresponsiveness and suppresses tumor development in simian virus 40 tumor antigen-transgenic mice. Proc. Natl Acad. Sci. USA 91, 3916–3920 (1994).
Google Scholar
Spadaro, M., Lanzardo, S., Curcio, C., Forni, G. & Cavallo, F. Immunological inhibition of carcinogenesis. Cancer Immunol. Immunother. 53, 204–216 (2004).
Google Scholar
Greiner, J. W., Zeytin, H., Anver, M. R. & Schlom, J. Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. Cancer Res. 62, 6944–6951 (2002).
Google Scholar
Lesterhuis, W. J. et al. Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients. Anticancer. Res. 30, 5091–5097 (2010).
Google Scholar
Suzuki, H., Graziano, D. F., McKolanis, J. & Finn, O. J. T cell-dependent antibody responses against aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease. Clin. Cancer Res. 11, 1521–1526 (2005).
Google Scholar
Broussard, E. K. et al. Identification of putative immunologic targets for colon cancer prevention based on conserved gene upregulation from preinvasive to malignant lesions. Cancer Prev. Res. 6, 666–674 (2013).
Google Scholar
Cappello, P. et al. Vaccination with ENO1 DNA prolongs survival of genetically engineered mice with pancreatic cancer. Gastroenterology 144, 1098–1106 (2013).
Google Scholar
Mennuni, C. et al. Preventive vaccination with telomerase controls tumor growth in genetically engineered and carcinogen-induced mouse models of cancer. Cancer Res. 68, 9865–9874 (2008).
Google Scholar
Corulli, L. R. et al. Multi-epitope-based vaccines for colon cancer treatment and prevention. Front. Immunol. 12, 729809 (2021).
Google Scholar
Chen, Y. T., Panarelli, N. C., Piotti, K. C. & Yantiss, R. K. Cancer-testis antigen expression in digestive tract carcinomas: frequent expression in esophageal squamous cell carcinoma and its precursor lesions. Cancer Immunol. Res. 2, 480–486 (2014).
Google Scholar
Merz, V. et al. Targeting KRAS: the elephant in the room of epithelial cancers. Front. Oncol. 11, 638360 (2021).
Google Scholar
Nasti, T. H. et al. Immunoprevention of chemical carcinogenesis through early recognition of oncogene mutations. J. Immunol. 194, 2683–2695 (2015).
Google Scholar
Holmstrom, M. O. & Andersen, M. H. Healthy donors harbor memory t cell responses to RAS neo-antigens. Cancers 12, 3045 (2020).
Google Scholar
Roudko, V. et al. Lynch syndrome and MSI-H cancers: from mechanisms to “off-the-shelf” cancer vaccines. Front. Immunol. 12, 757804 (2021). This article explores the mechanisms behind Lynch syndrome and MSI-H cancers, paving the way for the development of ‘off-the-shelf’ cancer vaccines tailored to these genetically defined cancers.
Google Scholar
Hernandez-Sanchez, A. et al. Vaccines for immunoprevention of DNA mismatch repair deficient cancers. J. Immunother. Cancer 10, e004416 (2022). This article emphasizes the potential of vaccines for the immunoprevention of cancers caused by DNA MMR deficiencies, highlighting advances in targeted vaccine strategies for patient populations at high risk.
Google Scholar
Mazumder, S. et al. Primary immunoprevention of epithelial ovarian carcinoma by vaccination against the extracellular domain of anti-mullerian hormone receptor II. Cancer Prev. Res. 10, 612–624 (2017). This article highlights the pioneering work in developing a vaccine targeting the extracellular domain of anti-Mullerian hormone receptor II, aiming to prevent epithelial ovarian carcinoma through primary immunoprevention.
Google Scholar
Iinuma, T. et al. Prevention of gastrointestinal tumors based on adenomatous polyposis coli gene mutation by dendritic cell vaccine. J. Clin. Invest. 113, 1307–1317 (2004).
Google Scholar
Bautz, D. J., Sherpa, A. T. & Threadgill, D. W. Prophylactic vaccination targeting ERBB3 decreases polyp burden in a mouse model of human colorectal cancer. Oncoimmunology 6, e1255395 (2017).
Google Scholar
Hance, K. W., Zeytin, H. E. & Greiner, J. W. Mouse models expressing human carcinoembryonic antigen (CEA) as a transgene: evaluation of CEA-based cancer vaccines. Mutat. Res. 576, 132–154 (2005).
Google Scholar
Hensel, J. A., Khattar, V., Ashton, R. & Ponnazhagan, S. Recombinant AAV-CEA tumor vaccine in combination with an immune adjuvant breaks tolerance and provides protective immunity. Mol. Ther. Oncolytics 12, 41–48 (2019).
Google Scholar
Ojima, T. et al. Successful cancer vaccine therapy for carcinoembryonic antigen (CEA)-expressing colon cancer using genetically modified dendritic cells that express CEA and T helper-type 1 cytokines in CEA transgenic mice. Int. J. Cancer 120, 585–593 (2007).
Google Scholar
Hurwitz, A. A. et al. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res. 60, 2444–2448 (2000).
Google Scholar
Degl’Innocenti, E. et al. Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization. Eur. J. Immunol. 35, 66–75 (2005).
Google Scholar
Gray, A. et al. Prostate cancer immunotherapy yields superior long-term survival in TRAMP mice when administered at an early stage of carcinogenesis prior to the establishment of tumor-associated immunosuppression at later stages. Vaccine 27, G52–G59 (2009).
Google Scholar
Boggio, K. et al. Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J. Exp. Med. 188, 589–596 (1998).
Google Scholar
Nanni, P. et al. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J. Exp. Med. 194, 1195–1205 (2001).
Google Scholar
Sakai, Y. et al. Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice. Cancer Res. 64, 8022–8028 (2004).
Google Scholar
De Giovanni, C. et al. Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2. Breast Cancer Res. 16, R10 (2014).
Google Scholar
Pupa, S. M. et al. Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination. Cancer Res. 65, 1071–1078 (2005).
Google Scholar
Xia, J. et al. Prevention of spontaneous breast carcinoma by prophylactic vaccination with dendritic/tumor fusion cells. J. Immunol. 170, 1980–1986 (2003).
Google Scholar
Steitz, J. et al. Evaluation of genetic melanoma vaccines in cdk4-mutant mice provides evidence for immunological tolerance against authochthonous melanomas in the skin. Int. J. Cancer 118, 373–380 (2006).
Google Scholar
Tormo, D. et al. Therapeutic efficacy of antigen-specific vaccination and toll-like receptor stimulation against established transplanted and autochthonous melanoma in mice. Cancer Res. 66, 5427–5435 (2006).
Google Scholar
Willimsky, G. & Blankenstein, T. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 437, 141–146 (2005).
Google Scholar
Beatty, P. L., Narayanan, S., Gariepy, J., Ranganathan, S. & Finn, O. J. Vaccine against MUC1 antigen expressed in inflammatory bowel disease and cancer lessens colonic inflammation and prevents progression to colitis-associated colon cancer. Cancer Prev. Res. 3, 438–446 (2010).
Google Scholar
Hochnadel, I. et al. Safety and efficacy of prophylactic and therapeutic vaccine based on live-attenuated Listeria monocytogenes in hepatobiliary cancers. Oncogene 41, 2039–2053 (2022).
Google Scholar
Vogt, A. et al. Immunoprevention of basal cell carcinomas with recombinant hedgehog-interacting protein. J. Exp. Med. 199, 753–761 (2004).
Google Scholar
Otahal, P., Schell, T. D., Hutchinson, S. C., Knowles, B. B. & Tevethia, S. S. Early immunization induces persistent tumor-infiltrating CD8+ T cells against an immunodominant epitope and promotes lifelong control of pancreatic tumor progression in SV40 tumor antigen transgenic mice. J. Immunol. 177, 3089–3099 (2006).
Google Scholar
Scott, B. A., Yarchoan, M. & Jaffee, E. M. Prophylactic vaccines for nonviral cancers. Annu. Rev. Cancer Biol. 2, 195–211 (2018).
Google Scholar
Kaur, A., Baldwin, J., Brar, D., Salunke, D. B. & Petrovsky, N. Toll-like receptor (TLR) agonists as a driving force behind next-generation vaccine adjuvants and cancer therapeutics. Curr. Opin. Chem. Biol. 70, 102172 (2022).
Google Scholar
Paston, S. J., Brentville, V. A., Symonds, P. & Durrant, L. G. Cancer vaccines, adjuvants, and delivery systems. Front. Immunol. 12, 627932 (2021).
Google Scholar
Yang, Y., Huang, C. T., Huang, X. & Pardoll, D. M. Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat. Immunol. 5, 508–515 (2004).
Google Scholar
Del Rosso, J. Q. The use of topical imiquimod for the treatment of actinic keratosis: a status report. Cutis 76, 241–248 (2005).
Google Scholar
Del Rosso, J. Q., Kircik, L., Goldenberg, G. & Brian, B. Comprehensive management of actinic keratoses: practical integration of available therapies with a review of a newer treatment approach. J. Clin. Aesthet. Dermatol. 7, S2–S12 (2014).
Google Scholar
Miller, J. D. et al. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 28, 710–722 (2008).
Google Scholar
Gulen, M. F. et al. Signalling strength determines proapoptotic functions of STING. Nat. Commun. 8, 427 (2017).
Google Scholar
Wherry, E. J. T cell exhaustion. Nat. Immunol. 12, 492–499 (2011).
Google Scholar
Dobson, S. R. et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA 309, 1793–1802 (2013).
Google Scholar
World Health Organization. Human papillomavirus vaccines: WHO position paper (2022 update). Wkly Epidemiol. Rec. 50, 645–672 (2022).
Bijker, M. S. et al. Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation. Eur. J. Immunol. 38, 1033–1042 (2008).
Google Scholar
Sahin, U. et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 547, 222–226 (2017).
Google Scholar
link
